Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-diabetic drug
Biotech
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
The expansion is driven by midphase Type 2 diabetes data suggesting tirzepatide improves markers associated with nonalcoholic steatohepatitis.
Nick Paul Taylor
Jun 10, 2019 9:00am
Regenerating insulin-producing cells with zinc in diabetes
Dec 7, 2018 9:45am
Novo Nordisk adds to diabetes plans with Evotec deal
Aug 23, 2018 9:22am
Takeda, Zinfandel ax Alzheimer’s test for pioglitazone
Jan 25, 2018 10:24am
Lilly pays $55M for rights to KeyBioscience’s diabetes assets
Jun 8, 2017 8:34am